Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Alland

Showing results (41-50 of 153) with videos related to

Pageof 16
Sort By:
Antimicrobial Agents and Chemotherapy|April 23, 2025
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosisHeena Soni, Sandeep Tyagi, Kishor Mane, et al.
Clinical and Vaccine Immunology : CVI|June 12, 2009
Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization ratesAzadeh Tasslimi, Erica J Sison, Elizabeth Story, et al.
Plos One|September 16, 2014
Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in UgandaWilly Ssengooba, Lydia Nakiyingi, Derek T Armstrong, et al.
Nature Medicine|August 15, 2006
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazidCatherine Vilchèze, Feng Wang, Masayoshi Arai, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
Decontaminating N95 respirators during the Covid-19 pandemic: simple and practical approaches to increase decontamination capacity, speed, safety and ease of useRiccardo Russo, Carly Levine, Courtney Veilleux, et al.
Journal of Clinical Microbiology|January 28, 2009
Use of sloppy molecular beacon probes for identification of mycobacterial speciesHiyam H El-Hajj, Salvatore A E Marras, Sanjay Tyagi, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2011
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditionsCatherine Vilchèze, Anthony D Baughn, JoAnn Tufariello, et al.
The Journal of Infectious Diseases|February 9, 2010
Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanismsAlifiya S Motiwala, Yang Dai, Edward C Jones-López, et al.
Tuberculosis (Edinburgh, Scotland)|March 11, 2018
Polymorphisms in Rv3806c (ubiA) and the upstream region of embA in relation to ethambutol resistance in clinical isolates of Mycobacterium tuberculosis from North IndiaAstha Giri, Shraddha Gupta, Hassan Safi, et al.
Molecular Microbiology|July 25, 2008
Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosisCatherine Vilchèze, Yossef Av-Gay, Rodgoun Attarian, et al.
Pageof 16

Showing results (41-50 of 153) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|April 23, 2025
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosisHeena Soni, Sandeep Tyagi, Kishor Mane, et al.
Clinical and Vaccine Immunology : CVI|June 12, 2009
Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization ratesAzadeh Tasslimi, Erica J Sison, Elizabeth Story, et al.
Plos One|September 16, 2014
Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in UgandaWilly Ssengooba, Lydia Nakiyingi, Derek T Armstrong, et al.
Nature Medicine|August 15, 2006
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazidCatherine Vilchèze, Feng Wang, Masayoshi Arai, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
Decontaminating N95 respirators during the Covid-19 pandemic: simple and practical approaches to increase decontamination capacity, speed, safety and ease of useRiccardo Russo, Carly Levine, Courtney Veilleux, et al.
Journal of Clinical Microbiology|January 28, 2009
Use of sloppy molecular beacon probes for identification of mycobacterial speciesHiyam H El-Hajj, Salvatore A E Marras, Sanjay Tyagi, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2011
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditionsCatherine Vilchèze, Anthony D Baughn, JoAnn Tufariello, et al.
The Journal of Infectious Diseases|February 9, 2010
Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanismsAlifiya S Motiwala, Yang Dai, Edward C Jones-López, et al.
Tuberculosis (Edinburgh, Scotland)|March 11, 2018
Polymorphisms in Rv3806c (ubiA) and the upstream region of embA in relation to ethambutol resistance in clinical isolates of Mycobacterium tuberculosis from North IndiaAstha Giri, Shraddha Gupta, Hassan Safi, et al.
Molecular Microbiology|July 25, 2008
Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosisCatherine Vilchèze, Yossef Av-Gay, Rodgoun Attarian, et al.
Pageof 16